Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
关键词:
摘要: Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of in poly(ethylene glycol)-coated (stealth) liposomes with prolonged circulation time and unique toxicity profile. We review the preclinical clinical pharmacology as well recent data obtained specific cancer types. Doxil retain drug payload during accumulate preferentially tissues increased microvascular permeability, often case tumors. profile drastically different from that doxorubicin, characterized by dominant dose-limiting mucocutaneous toxicities, mild myelosupression, minimal alopecia, no apparent cardiac toxicity. Although single maximum tolerated dose (MTD) actually lower than conventionally administered cumulative MTD may be substantially greater free doxorubicin. probably one most active agents AIDS-related Kaposi's sarcoma an...
informahealthcare.com参考文章(72)
D. Papahadjopoulos, T. M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S. K. Huang, K. D. Lee, M. C. Woodle, D. D. Lasic, C. Redemann, Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 88, pp. 11460- 11464 ,(1991) , 10.1073/PNAS.88.24.11460
Alberto A. Gabizon, Orit Pappo, Dorit Goren, Michal Chemla, Dinah Tzemach, Aviva T. Horowitz, Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated Liposomes Journal of Liposome Research. ,vol. 3, pp. 517- 528 ,(1993) , 10.3109/08982109309150734
Timothy Sullivan, John Yarrington, Mary S. Newman, Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes Journal of Pharmacology and Experimental Therapeutics. ,vol. 289, pp. 1128- 1133 ,(1999)
H.J. Burstein, M.J. Ramirez, W.P. Petros, K.D. Clarke, M.A. Warmuth, P.K. Marcom, U.A. Matulonis, L.M. Parker, L.N. Harris, E.P. Winer, Phase I study of Doxil and vinorelbine in metastatic breast cancer Annals of Oncology. ,vol. 10, pp. 1113- 1116 ,(1999) , 10.1023/A:1008323200102
A. Gabizon, M. Chemla, D. Tzemach, A. T. Horowitz, D. Goren, Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. Journal of Drug Targeting. ,vol. 3, pp. 391- 398 ,(1996) , 10.3109/10611869608996830
J. W. Park, K. Hong, P. Carter, H. Asgari, L. Y. Guo, G. A. Keller, C. Wirth, R. Shalaby, C. Kotts, W. I. Wood, Development of anti-p185HER2 immunoliposomes for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 1327- 1331 ,(1995) , 10.1073/PNAS.92.5.1327
Alberto Gabizon, Shimon Amselem, Dorith Goren, Rivka Cohen, Shulamith Druckmann, Ilana Fromer, Roland Chisin, Tamar Peretz, Aaron Sulkes, Yechezkel Barenholz, Preclinical and Clinical Experience with a Doxorubicin-Liposome Preparation Journal of Liposome Research. ,vol. 1, pp. 491- 502 ,(1990) , 10.3109/08982109009036010
T. Safra, F. Muggia, S. Jeffers, D.D. Tsao-Wei, S. Groshen, O. Lyass, R. Henderson, G. Berry, A. Gabizon, Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 Annals of Oncology. ,vol. 11, pp. 1029- 1033 ,(2000) , 10.1023/A:1008365716693
Victor Fei Pang, Yun Long Tseng, Fu Hsiung Chang, Jim Jen Liu, Shui Tsung Chen, Chang Jen Huang, Ruey Long Hong, Direct Comparison of Liposomal Doxorubicin with or without Polyethylene Glycol Coating in C-26 Tumor-bearing Mice Is Surface Coating with Polyethylene Glycol Beneficial? Clinical Cancer Research. ,vol. 5, pp. 3645- 3652 ,(1999)
Simcha Even-Chen, Yechezkel Barenholz, Eli Kedar, Alberto Gabizon, Anna Cabanes, Jacqueline Zimberoff, Enhancement of Antitumor Activity of Polyethylene Glycol-coated Liposomal Doxorubicin with Soluble and Liposomal Interleukin 2 Clinical Cancer Research. ,vol. 5, pp. 687- 693 ,(1999)